Differential gene expression-based connectivity mapping identified novel drug candidate and improved Temozolomide efficacy for Glioblastoma

BACKGROUND: Glioblastoma (GBM) has a devastating median survival of only one year. Treatment includes resection, radiation therapy, and temozolomide (TMZ); however, the latter increased median survival by only 2.5 months in the pivotal study. A desperate need remains to find an effective treatment....

Descripción completa

Detalles Bibliográficos
Autores principales: Vengoji, Raghupathy, Atri, Pranita, Macha, Muzafar A., Seshacharyulu, Parthasarathy, Perumal, Naveenkumar, Mallya, Kavita, Liu, Yutong, Smith, Lynette M., Rachagani, Satyanarayana, Mahapatra, Sidharth, Ponnusamy, Moorthy P., Jain, Maneesh, Batra, Surinder K., Shonka, Nicole
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8543939/
https://www.ncbi.nlm.nih.gov/pubmed/34696786
http://dx.doi.org/10.1186/s13046-021-02135-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8543939/
https://www.ncbi.nlm.nih.gov/pubmed/34696786
http://dx.doi.org/10.1186/s13046-021-02135-x

Ejemplares similares